Physician profile
Vicky Wong
NPI 1659620516
$11,335.33
in general payments reported to CMS, 2019-2025
21 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,994 · 2020: $466 · 2021: $924 · 2022: $965 · 2023: $2,638 · 2024: $1,577 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,487 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,486.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,550.21 | 2022-2025 | Infuse, Biotrue, Miebo |
| Alcon Vision LLC | $2,282.91 | 2019-2025 | Total30, Precision 1, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,763.18 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $963.06 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Coopervision INC. | $612.77 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Paragon Crt |
| Dompe US, INC. | $431.21 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $401.59 | 2023-2025 | |
| Johnson & Johnson Vision Care, INC. | $394.52 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $343.55 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $305.87 | 2019-2023 | |
| Lkc Technologies, INC. | $298.20 | 2024-2025 | |
| Allergan, INC. | $269.82 | 2019-2022 | |
| Optos, INC. | $213.79 | 2019 | |
| Kala Pharmaceuticals, INC. | $143.91 | 2021 | |
| Eyevance Pharmaceuticals LLC | $108.04 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $83.43 | 2022-2024 | Tyrvaya |
| Shire North American Group INC | $68.54 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $34.86 | 2019 | |
| Visioneering Technologies, INC. | $23.14 | 2022 | |
| Plexus Optix, INC. | $22.44 | 2021 | |
| Harrow Eye, LLC | $20.29 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.